Literature DB >> 8411234

Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency.

P Houyau, C Gay, E Chatelut, P Canal, H Roché, G Milano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8411234     DOI： 10.1093/jnci/85.19.1602

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  13 in total

1.  Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.

Authors:  X Wei; H L McLeod; J McMurrough; F J Gonzalez; P Fernandez-Salguero
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 2.  Pharmacogenetics: a tool for individualizing antineoplastic therapy.

Authors:  F Innocenti; L Iyer; M J Ratain
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 3.  The oral fluorinated pyrimidines.

Authors:  J S de Bono; C J Twelves
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

Review 4.  How may anticancer chemotherapy with fluorouracil be individualised?

Authors:  Su-arpa Ploylearmsaeng; Uwe Fuhr; Alexander Jetter
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 5.  Pharmacology of fluorinated pyrimidines: eniluracil.

Authors:  S D Baker
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

Review 6.  Clinical pharmacokinetics of capecitabine.

Authors:  B Reigner; K Blesch; E Weidekamm
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Mutations at codon 974 of the DPYD gene are a rare event.

Authors:  S A Ridge; O Brown; J McMurrough; P Fernandez-Salguero; W E Evans; F J Gonzalez; H L McLeod
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy.

Authors:  Sherry Morgan-Meadows; James P Thomas; Daniel Mulkerin; Jordan D Berlin; Howard Bailey; Kim Binger; Jennifer Volkman; Dona Alberti; Chris Feierabend; Rebecca Marrocha; Rhoda Z Arzoomanian; George Wilding
Journal:  Invest New Drugs       Date:  2002-11       Impact factor: 3.850

Review 9.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

10.  Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.

Authors:  S A Ridge; J Sludden; X Wei; A Sapone; O Brown; S Hardy; P Canney; P Fernandez-Salguero; F J Gonzalez; J Cassidy; H L McLeod
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.